Israeli pharmaceutical company Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) announced on Wednesday that its subsidiary BI Sky Global (BI) has completed the Human Repeated Insult Patch Test (HRIPT) for Sensitisation and Irritation Testing, ensuring the safety of its cosmetic products.

HRIPT is the personal care industry's standard safety test for cosmetic, OTC drug and topical medical devices.

Innocan Pharma also announced that in 2024 it surpassed the sales milestone of an average of 5,000 units per day.

Roni Kamhi, CEO of BI Sky Global, said: "Successfully completing the HRIPT testing and achieving a sales milestone of 5,000 units per day on average underscores our strong commitment to providing the highest quality products that are in demand by the market. This positions us very well for further expansion in sales and marketing as we capitalise on our success and bring the highest quality products to market."